The Plot Twist Medicine Didn't See Coming
Here's something wild: the drug that might save children with one of the world's rarest diseases has been around since the 1970s. It's been treating sleeping sickness in Africa, helping women with unwanted facial hair, and preventing cancer recurrence in neuroblastoma patients. But nobody thought to try it for Bachmann-Bupp syndrome—until now.
This is exactly the kind of "accidental discovery" that reminds me why I love science. Sometimes breakthroughs don't come from billion-dollar research programs. They come from a chance conversation between researchers who are willing to think creatively.
So What's This Drug, Anyway?
The medication is called difluoromethylornithine (try saying that three times fast!), or DFMO for short. You might also know it by its brand name, eflornithine. It's been doing useful work in medicine for decades, but it was kind of the reliable workhorse that nobody got excited about—until doctors realized it could tackle something completely different.
The beautiful part? It works almost perfectly for this disease. Let me explain why without getting too sciency on you.
Understanding the Problem (Without the Jargon)
Bachmann-Bupp syndrome is caused by mutations in a gene called ODC1. Think of your genes like instruction manuals for your body. This particular mutation writes bad instructions—it tells certain proteins to work way too hard. The result? Kids with BABS experience developmental delays, weak muscle tone, and hair loss. It's serious stuff, and until recently, there wasn't much doctors could do about it.
Here's where DFMO comes in like a hero: it specifically blocks the overactive protein that the mutated gene is producing. It's like turning down the volume on a speaker that's been stuck at maximum. The drug directly targets the problem at its source.
The Real Talk: Only 20 Cases Exist
Let me be honest about what makes this both heartbreaking and hopeful. There are only about 20 known cases of Bachmann-Bupp syndrome in the entire world. That's heartbreaking because these families are incredibly rare. But it's also hopeful because it means every single patient could potentially get treatment—assuming we can organize it properly.
This is where things get complicated, though. Trying to run clinical trials for a disease that affects maybe 20 people globally is like trying to fill a stadium with people who have a specific birthday. The regulatory systems and study frameworks were basically built for common diseases, not extreme rarities.
How a Nonprofit Became the Game-Changer
This is the part of the story I find genuinely inspiring. A nonprofit organization called Every Cure decided to jump in and help. Their whole mission is simple: take drugs that already exist and figure out if they can treat different diseases. No need to invent new drugs. Just get creative with old ones.
They partnered with Corewell Health and Michigan State University to do something that honestly should probably happen more often: they cut through the red tape. They're helping with the preclinical studies, increasing awareness among doctors (because honestly, most physicians have never heard of BABS), and creating systems to actually find and treat patients when they're identified.
Dr. Caleb Bupp, the pediatric geneticist who helped discover BABS in the first place, described it perfectly: "They are opening doors that we never would have been able to crack open."
Why This Matters Beyond One Rare Disease
Here's what gets me excited about this story: it's not really about one obscure genetic disorder. It's about a whole different way of thinking about medicine.
We spend billions developing brand-new drugs. That's important! But there are probably thousands of existing medications sitting in pharmacies right now that could help people with different conditions if someone would just... try. Every Cure is basically saying, "What if we got smarter about matching old drugs to new problems?"
It's economical, it's faster, and honestly, it's the kind of creative problem-solving that can actually save lives without waiting 10+ years for traditional drug development.
The Road Ahead
The team is starting preclinical studies next year, which is a huge milestone. They're building a stronger scientific foundation, documenting everything, and preparing to eventually run a formal clinical trial. It won't be quick—but for families dealing with BABS, the hope alone is probably worth more than you can measure.
The first patient to receive DFMO was Marley Berthoud from Michigan. Then five more patients started treatment, with encouraging early results. That's not a large clinical trial by traditional standards, but for a disease that 99.99% of doctors have never encountered, it's actually significant.
The Bottom Line
This story reminds me that medicine isn't always about flashy new inventions. Sometimes it's about smart people asking the right questions: "Wait, what if we tried something we already have?" It's about collaboration, persistence, and refusing to accept that "rare" has to mean "hopeless."
For the families of Bachmann-Bupp syndrome patients, that combination is literally life-changing.